Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment

Biological Psychiatry

Volumn 56, Issue 4, 2004, Pages 279-283

  Fellgiebel, Andreas ^a   Siessmeier, Thomas ^a   Scheurich, Armin ^a   Winterer, Georg ^a   Bartenstein, Peter ^a   Schmidt, Lutz G ^a   Müller, Matthias J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Alzheimer disease; biomarker; early diagnosis; FDG PET; MCI; mild cognitive impairment; phospho tau

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN CHEMISTRY; BRAIN MAPPING; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4143138616     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.05.014     Document Type: Article

References (33)

1. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl. 179:2003;47-51
2. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl). 103:2002;26-35
3. Bartenstein P., Minoshima S., Hirsch C., Buch K., Willoch F., Mösch D., et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by single photon emission computed tomography. J Nucl Med. 38:1997;1095-1101
4. Berent S., Giordani B., Foster N., Minoshima S., Lajiness-O'Neill R., Koeppe R., et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Psychiatry Res. 33:1999;7-16
5. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 26:1995;231-245
6. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59:2002;627-629
7. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 59:2002;1267-1272
8. Chetelat G., Desgranges B., de la Sayette V., Viader F., Berkouk K., Landeau B., et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain. 126:2003;1955-1967
9. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.C. Mild cognitive impairment can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 60:2003;1374-1377
10. Desgranges B., Baron J.C., de la Sayette V., Petit-Taboue M.C., Benali K., Landeau B., et al. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain. 121:2003;611-631
11. Desgranges B., Baron J.C., Lalevee C., Giffard B., Viader F., de La Sayette V., et al. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET relationship to degree of deterioration. Brain. 125:2002;1116-1124
12. Drzezga A., Arnold S., Minoshima S., Noachtar S., Szecsi J., Winkler P., et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy evaluation of an observer-independent analysis. J Nucl Med. 40:1999;737-746
13. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease a PET follow-up study. Eur J Nucl Med Mol Imaging. 30:2003;1104-1113
14. Hampel H., Goernitz A., Buerger K. Advances in the development of biomarkers for Alzheimer's disease from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull. 61:2003;243-253
15. Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frölich L., et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 17:2002;302-316
16. International Federation of Clinical Chemistry. Expert panel on theory of reference values and international committee on reference values. Approved recommendation on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta. 170:1987;813-832
17. Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 50:2001;150-156
18. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 36:1995;1238-1248
19. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 42:1997;85-94
20. Morris J.C. The Clinical Dementia Rating (CDR) current version and scoring rules. Neurology. 43:1993;2412-2414
21. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 58:2001;397-405
22. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Arch Neurol. 58:2001;1985-1992
23. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment clinical characterization and outcome. Arch Neurol. 56:1999;303-308
24. Schönknecht P., Pantel J., Hunt A., Volkmann M., Buerger K., Hampel H., et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett. 339:2003;172-174
25. Sibson N.R., Dhankhar A., Mason G.F., Rothman D.L., Behar K.L., Shulman R.G. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A. 95:1998;316-321
26. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., et al. Positron emission tomography in evaluation of dementia regional brain metabolism and long-term outcome. JAMA. 286:2001;2120-2127
27. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab. 1:1981;7-36
28. Thalmann B., Monsch A., Schneitter M. CERAD neuropsychological battery a minimal data set to be used as a common assessment tool of dementia. Neurobiol Aging. 19:1998;S9
29. Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Nores A., Nadon G., et al. Prediction of probable Alzheimer's disease in memory-impaired patients a prospective longitudinal study. Neurology. 46:1996;661-665
30. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 285:2000;49-52
31. Welsh K.A., Butters N., Mohs R.C., Beekly D., Edland S., Fillenbaum G., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 44:1994;609-614
32. Xu G., Meyer J.S., Thornby J., Chowdhury M., Quach M. Screening for mild cognitive impairment (MCI) utilizing combined mini-mental-cognitive capacity examinations for identifying dementia prodromes. Int J Geriatr Psychiatry. 17:2002;1027-1033
33. Zuendorf G., Kerrouche N., Herholz K., Baron J.C. Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum Brain Mapp. 18:2003;13-21